

METHOD FOR THE PROGNOSIS OF MELANOMA

ALMA MATER STUDIORUM-UNIVERSITÀ DI BOLOGNA



Method to determine the prognosis and / or staging of a cutaneous melanoma, based on measurement of specific microRNAs, whose expression correlates with the Breslow thickness

Protection: International

Inventors: Emi Dika, Manuela Ferracin, Mattia Riefolo

INVENTION

Currently the staging and prognosis of cutaneous melanoma are based on the measurement of Breslow thickness (BT), which is the measurement of the melanoma thickness, executed with an ocular micrometer by an expert operator.

The inventors have developed and tested a method based on the quantification of three specific microRNAs (quantitative PRC) for the assessment of melanoma. The quantification of these microRNAs could be used as a new molecular diagnostic parameter of melanoma prognosis since the microRNAs quantity correlates with Breslow's thickness. In this way, the clinician can base patient treatments on more solid and objective basis.

ADVANTAGES

- Effective even when the evaluation with standard technique is uncertain/not definitive
- Overcome inter-observer variability
- No specific technical expertise is needed for the interpretation

APPLICATIONS

- Diagnostic test for objective staging of melanoma.

CONTACTS

Knowledge Transfer Office

www.unibo.it/patents

051 20 80 631

kto@unibo.it



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA